RLMD · XBRL financial data

Relmada Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RLMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	35,973	90,622	113,323	54,807	46,176	26,879
General and administrative	24,866	35,082	47,926	48,895	37,716	32,221
Total operating expenses	60,839	125,703	161,249	103,702	83,891	59,100
Operating income (loss)	(60,839)	(125,703)	(161,249)	(103,702)	(83,891)	(59,100)
Interest income	—	—	—	5,152	3,530	1,396
Net income (loss)	(59,456)	(125,752)	(157,044)	(98,792)	(79,979)	(57,385)
Earnings per share, basic USD per share	—	(7.16)	(5.30)	(3.28)	(2.65)	(1.45)
Earnings per share, diluted USD per share	—	(7.16)	(5.30)	(3.28)	(2.65)	(1.45)
Weighted average shares, basic thousands of shares	—	17,553	29,629	30,099	30,164	39,480
Weighted average shares, diluted thousands of shares	—	17,553	29,629	30,099	30,164	39,480

Fiscal years (RLMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,495	44,443	5,396	4,092	3,857	3,497
Short-term investments	114,596	167,466	142,927	92,232	41,052	89,510
Total current assets	118,074	223,298	152,870	97,509	45,796	93,984
Property and equipment, net	1	—	—	—	—	—
Total assets	118,186	223,326	152,905	97,552	45,818	94,003
Accounts payable	8,346	11,193	5,262	3,506	4,131	1,569
Accrued liabilities	4,257	3,868	7,207	8,689	6,161	4,862
Total current liabilities	12,603	15,061	12,469	12,195	10,291	6,431
Total liabilities	12,603	15,061	12,469	12,195	10,296	7,491
Accumulated deficit	(179,315)	(305,067)	(462,111)	(560,903)	(640,882)	(698,267)
Total stockholders' equity	105,583	208,265	140,436	85,357	35,522	86,512
Total liabilities and equity	118,186	223,326	152,905	97,552	45,818	94,003
Common shares outstanding (cover page) thousands of shares	16,746	29,369	30,099	30,174	33,192	104,890

Fiscal years (RLMD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(59,456)	(125,752)	(157,044)	(98,792)	(79,979)	(57,385)
Stock-based compensation	20,777	40,494	44,195	43,811	30,184	13,905
Net cash from operating activities	(27,809)	(91,873)	(103,802)	(51,659)	(51,756)	(45,787)
Net cash from investing activities	(34,448)	(54,118)	19,734	50,453	51,562	(48,138)
Proceeds from issuing common stock	17,840	184,643	42,729	—	—	93,638
Proceeds from issuing equity	19,792	—	—	—	—	—
Net cash from financing activities	28,473	187,939	45,020	(98)	(40)	93,565

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Relmada Therapeutics	11,334	not reported	(9,606)*	106.7M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
CEL-SCI	6,527	not reported	(4,031)*	17.6M	1.6 quarters	Q3 FY26 10-QJun 30, 2026
IGC Pharma	331	265	(1,350)*	103.4M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Cognition Therapeutics	34,012	not reported	(3,053)*	95.1M	11.1 quarters	Q2 FY26 10-QJun 30, 2026
Charlie's Holdings	527	not reported	(383)*	280.6M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Ernexa Therapeutics	5,028	not reported	(4,152)*	1.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Marker Therapeutics	11,331	not reported	(3,716)*	16.7M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Fibrogen	50,644	(1,474)	(3,991)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026
Armata Pharmaceuticals	23,952	not reported	(8,666)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.